ARTAN Bio

ARTHEx Biotech

This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.

Code Bio

This company develops non-viral genetic medicine delivery platforms and therapies for patients with rare and prevalent genetic diseases.

Spot Biosystems

This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.

Anjarium BioSciences

This company develops non-viral gene therapies and synthetic DNA vectors for patients with genetic diseases and life sciences researchers.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

Stridebio

This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.

Borea Therapeutics

The company develops bio-conjugated viral vectors for gene therapy to treat patients with genetic or chronic diseases.

Typewriter Therapeutics

The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.